

Annual Review of Statistics and Its Application On p-Values and Bayes Factors

Leonhard Held and Manuela Ott

Epidemiology, Biostatistics and Prevention Institute, University of Zurich, CH-8001 Zurich, Switzerland; email: leonhard.held@uzh.ch, manuela.ott@uzh.ch

Annu. Rev. Stat. Appl. 2018. 5:393-419

First published as a Review in Advance on December 8, 2017

The Annual Review of Statistics and Its Application is online at statistics.annualreviews.org

https://doi.org/10.1146/annurev-statistics-031017-100307

Copyright © 2018 by Annual Reviews. All rights reserved



- Download figures as PPT slides
- Navigate linked references
- Download citations
 Explore related articles
- Explore related anti
 Search keywords

Keywords

Bayes factor, evidence, minimum Bayes factor, objective Bayes, *p*-value, sample size

Abstract

The *p*-value quantifies the discrepancy between the data and a null hypothesis of interest, usually the assumption of no difference or no effect. A Bayesian approach allows the calibration of *p*-values by transforming them to direct measures of the evidence against the null hypothesis, so-called Bayes factors. We review the available literature in this area and consider two-sided significance tests for a point null hypothesis in more detail. We distinguish simple from local alternative hypotheses and contrast traditional Bayes factors based on the data with Bayes factors based on *p*-values or test statistics. A well-known finding is that the minimum Bayes factor, the smallest possible Bayes factor within a certain class of alternative hypotheses, provides less evidence against the null hypothesis than the corresponding *p*-value might suggest. It is less known that the relationship between *p*-values and minimum Bayes factors also depends on the sample size and on the dimension of the parameter of interest. We illustrate the transformation of *p*-values to minimum Bayes factors with two examples from clinical research.

1. INTRODUCTION

*p***-Value:** the probability, under the

assumption of no effect, of obtaining a result equal to or more extreme than what was actually observed

One-sided *p*-value:

based on the probabilities of extreme values in one prespecified direction of a point null hypothesis The *p*-value is the probability, under the assumption of no association or no effect (the null hypothesis H_0), of obtaining a result equal to or more extreme than what was actually observed (Goodman 2005). *p*-Values for point null hypotheses still dominate most of the applied literature (Greenland & Poole 2013), despite the fact that *p*-values are commonly misused (Wasserstein & Lazar 2016, Matthews et al. 2017). Specifically, a quantitative interpretation of *p*-values beyond the traditional dichotomization into significant and nonsignificant has caused much confusion, and misinterpretations are commonplace. Most prominent is the widespread belief that the *p*-value is the probability of a chance finding, i.e., the probability of the null hypothesis, but many other misinterpretations can also be found (Goodman 2008, Greenland et al. 2016).

A first step toward a quantitative interpretation of *p*-values is a categorization into more than two levels, making a step away from the Neyman-Pearson hypothesis test paradigm to Fisher's significance test. Cox & Donnelly (2011, p. 147) give the following guidelines to interpret *p*-values as measures of evidence against a null hypothesis H_0 : If $p \simeq 0.1$ there is "a suggestion of evidence" against H_0 , if $p \simeq 0.05$ there is "modest evidence" against H_0 , and if $p \simeq 0.01$ there is "strong evidence" against H_0 . Bland (2015, section 9.4) suggests a similar rough guide with five levels, reproduced in **Table 1**. Similar categories have been proposed in many other applied statistics textbooks, for example, Ramsey & Schafer (2002).

However, such categorizations always carry a level of arbitrariness. In addition, *p*-values are only indirect measures of evidence: A *p*-value is computed under the assumption that the null hypothesis H_0 is true, so it is conditional on H_0 . It does not allow for conclusions about the probability of H_0 given the data, which is usually of primary interest. More precisely, a *p*-value is a quantitative measure of discrepancy between the data and the point null hypothesis H_0 (Goodman 1999a). But, as Cox (2006, p. 83) puts it, "conclusions expressed in terms of probability are on the face of it more powerful than those expressed indirectly via confidence intervals and *p*-values." Such direct conclusions can be obtained by using Bayes factors. Assuming an alternative hypothesis H_1 has also been specified, the Bayes factor directly quantifies whether the data have increased or decreased the odds of H_0 . A better approach than categorizing a *p*-value is thus to transform a *p*-value to a Bayes factor or a lower bound on a Bayes factor, a so-called minimum Bayes factor (Goodman 1999b). But many such ways have been proposed to calibrate *p*-values, and there is currently no consensus on how *p*-values should be transformed to Bayes factors.

First, there is an important distinction between tests for direction and tests for existence (Marsman & Wagenmakers 2017). Tests for direction investigate whether the parameter of interest is above or below a specific value, assuming that there is an effect. For example, a test for direction can be used to assess whether a treatment effect is positive or negative. Tests for direction are usually conducted with one-sided *p*-values, and there is a close correspondence to the Bayesian

	Strength of evidence against H_0		
<i>p</i> -Value	Bland (2015)	Cox & Donnelly (2011)	
>0.1	Little or no evidence		
0.1 to 0.05	Weak evidence	A suggestion of evidence	
0.05 to 0.01	Evidence	Modest evidence	
0.01 to 0.001	Strong evidence	Strong evidence	
< 0.001	Very strong evidence		

Table 1Categorization of p-values into levels of evidence against H_0

Cox & Donnelly (2011) specify the amount of evidence of specific *p*-values ($p \simeq 0.1, 0.05$, and 0.01), which correspond to certain cut points in the categorization by Bland (2015).

approach based on the posterior probability that the effect is positive or negative. In fact, this posterior probability is often equal or approximately equal to the one-sided *p*-value, if a noninformative prior is used (Casella & Berger 1987). A simple example is given by Lee (2004, section 4.2).

In contrast, tests for existence aim to summarize the evidence against the point null hypothesis of no effect. Tests for existence can be conducted with one-sided or two-sided *p*-values, but the correspondence of the *p*-value to the Bayesian posterior probability of the null is now lost and care has to be taken to transform *p*-values to Bayes factors.

In this article, we consider tests for existence. We review different methods being proposed to calibrate p-values, identify problems with some of the proposed methods, and give general recommendations for how to transform p-values to (minimum) Bayes factors. We emphasize that this transformation depends on how the p-value has been calculated. Specifically, the sample size and the dimension of the parameter of interest both matter. It also matters whether the p-value came from a study with a well-defined alternative hypothesis or from a study used to generate possible hypotheses.

1.1. Bayes Factors

Consider a significance test for existence with a point null hypothesis $H_0: \theta = \theta_0$, where the parameter of interest θ may be a scalar or a vector. In many problems $\theta_0 = 0$, for example, when testing if there is evidence for a difference θ between two treatment groups. The alternative hypothesis may be simple, i.e., $H_1: \theta = \theta_1 \neq \theta_0$, or composite, usually $H_1: \theta \neq \theta_0$. In the latter case, a Bayesian approach now requires a prior distribution $f(\theta | H_1)$ to be specified. Local alternatives, represented by a unimodal symmetric prior distribution centered around the null value θ_0 , are the common choice. In contrast, nonlocal alternatives (Johnson & Rossell 2010) have zero probability mass in a neighborhood of θ_0 , with the simple alternative $H_1: \theta = \theta_1 \neq \theta_0$ being a special case.

The Bayes factor (BF) transforms the prior odds $Pr(H_0)/Pr(H_1)$ [where $Pr(H_1) = 1 - Pr(H_0)$] to the posterior odds $Pr(H_0 | y)/Pr(H_1 | y)$ in the light of the data y:

$$\frac{\Pr(H_0 \mid y)}{\Pr(H_1 \mid y)} = \operatorname{BF}(y) \cdot \frac{\Pr(H_0)}{\Pr(H_1)}.$$
1

The Bayes factor BF(y) thus is a direct quantitative measure of how the data y have increased or decreased the odds of H_0 , regardless of the actual value of the prior probability $Pr(H_0)$. The Bayes factor (or its logarithm) is therefore often referred to as the strength of evidence or weight of evidence (Good 1950, Bernardo & Smith 2000). If necessary, we may add an index to BF(y), where BF₀₁(y) stands for " H_0 versus H_1 ," so BF₁₀(y) = 1/BF₀₁(y).

In Equation 1, the Bayes factor

$$BF(y) = \frac{f(y \mid H_0)}{f(y \mid H_1)}$$
 2.

is the ratio of the likelihood $f(y | H_0) = f(y | \theta = \theta_0)$ of the observed data y under the null hypothesis H_0 and the likelihood

$$f(y \mid H_1) = \int f(y \mid \theta) f(\theta \mid H_1) d\theta \qquad 3.$$

under the alternative hypothesis H_1 . For a simple alternative, Equation 3 reduces to the ordinary likelihood $f(y | H_1) = f(y | \theta = \theta_1)$, and the Bayes factor (Equation 2) reduces to a likelihood ratio. In general Equation 3 represents a marginal likelihood, i.e., the average likelihood $f(y | \theta)$ with respect to the prior distribution $f(\theta | H_1)$ for θ under the alternative H_1 (Kass & Raftery 1995). Note that the computation of the Bayes factor via Equation 2 does not require the specification of the prior probability $Pr(H_0)$.

Two-sided *p***-value:** based on the probabilities of extreme values in both directions of a point null hypothesis

Local alternatives:

a unimodal symmetric prior distribution of alternatives centered around the null value

Bayes factor:

compares the likelihood of the data y under the null hypothesis H_0 to the likelihood under the alternative hypothesis H_1

Marginal likelihood:

the average likelihood with respect to a prior distribution for alternative hypotheses

	Strength of evidence against H_0		
Bayes factor	Jeffreys (1961)	Goodman (1999b)	Held & Ott (2016)
1 to 1/3	Bare mention		Weak
1/3 to 1/10	Substantial	Weak to moderate	Moderate
1/10 to 1/30	Strong	Moderate to strong	Substantial
1/30 to 1/100	Very strong	Strong	Strong
1/100 to 1/300	Decisive	Very strong	Very strong
<1/300			Decisive

Table 2 Categorization of Bayes factors $BF \le 1$ into levels of evidence against H_0

Jeffreys actually used the slightly different cut points $(1/\sqrt{10})^a$, a = 1, 2, 3, 4, whereas Goodman specified evidence categories "weak," "moderate," "moderate to strong," and "strong to very strong" for Bayes factors of 1/5, 1/10, 1/20, and 1/100, respectively, which we have modified and aligned with our cut points.

In this article we focus on the evidence against a point null hypothesis provided by small Bayes factors $BF_{01} \leq 1$, such that Bayes factors lie in the same range as *p*-values, which facilitates comparisons. To categorize such Bayes factors, Held & Ott (2016) provided a six-grade scale reproduced in **Table 2**, which was proposed as a compromise of the grades proposed by Jeffreys (1961, appendix B) and Goodman (1999b, tables 1 and 2) (also shown in **Table 2**).

Communication of Bayes factors is of central importance. The categories shown in **Table 2** are helpful in this respect, but there remains a level of arbitrariness in the definition of the category levels. Ideally, the Bayes factor itself should be reported, and comprehensive formatting of Bayes factors is now crucial. We recommend presenting Bayes factors as ratios, for example, $BF_{01} = 1/7$, since this underlines the symmetry of Bayes factors if numerator and denominator are exchanged—here, $BF_{10} = 7/1$. For Bayes factors smaller than 1/10, say, it is usually sufficient to report Bayes factors in the 1/x format, where x is an integer. If the Bayes factor is larger, then we recommend using an additional decimal place for x, e.g., BF=1/2.5 or BF=1/1.3, to achieve better accuracy.

The Bayes factor (Equation 2) is based on the data y and is sometimes called a data-based Bayes factor (Held et al. 2015) to distinguish it from Bayes factors based on test statistics or p-values. Indeed, the step from a p-value p to a Bayes factor is most easily accomplished by treating p as the data y in Equation 2 to obtain a p-based Bayes factor based on the sampling distribution of p under H_0 and H_1 :

$$BF(p) = \frac{f(p \mid H_0)}{f(p \mid H_1)}.$$
4.

The distribution $f(p | H_0)$ of a two-sided *p*-value *p* under H_0 can usually be assumed to be uniform, since the corresponding Neyman-Pearson hypothesis test is constructed to maintain any type-I error rate α , i.e., $\Pr(p \le \alpha | H_0) = \alpha$ for all $\alpha \in (0, 1)$, and so $f(p | H_0) = 1$ for all *p* and therefore $BF(p) = 1/f(p | H_1)$. The distribution $f(p | H_1)$ will depend on the specific problem considered; see Hung et al. (1997) for a comprehensive study and Donahue (1999) for a specific example. A simple option is to directly specify a distribution for $p | H_1$, for example, a beta distribution. *p*-Based Bayes factors are particularly useful if the *p*-value is available but the underlying data are not.

The other option is to back-transform p to the underlying test statistic t, which was used to calculate p. If this transformation is one-to-one, then t = t(p) is well defined and it is easy to see that the Bayes factor does not change if we use t rather than p:

$$BF(t) = \frac{f_t(t(p) \mid H_0)}{f_t(t(p) \mid H_1)} = \frac{f_p(p \mid H_0)}{f_p(p \mid H_1)} = BF(p),$$
5.

p-Based Bayes

factor: a Bayes factor that is based on the sampling distributions of the *p*-value since $f_t(t(p) | H_i) = f_p(p | H_i) |dt(p)/dp|^{-1}$ for i = 0, 1. A Bayes factor BF(t) based on a test statistic t is a so-called test-based Bayes factor (Johnson 2005) and often constitutes the most convenient way to transform a *p*-value to a Bayes factor. However, a test-based Bayes factor may not be equal to a *p*-based Bayes factor if the transformation from t to p is not one-to-one. Then the *p*-based Bayes factor (Equation 4) is preferred, since it is directly based on the *p*-value, the quantity of interest.

1.2. Minimum Bayes Factors

The distribution $f(p | H_1)$ in Equation 4 may depend on unknown parameters η , say, and the maximum likelihood estimate $\hat{\eta}_{ML}$ of η for the observed *p*-value *p* can then be used to determine the minimum *p*-based Bayes factor as follows:

$$\min BF(p) = \frac{f(p \mid H_0)}{\max_{\eta} f(p \mid \eta, H_1)} = \frac{f(p \mid H_0)}{f(p \mid \hat{\eta}_{ML}, H_1)}.$$

If the transformation from *t* to *p* is one-to-one, then the minimum test-based Bayes factor based on Equation 5 will also be the same as the minimum *p*-based Bayes factor (Equation 6) if $f_t(t(p) | \eta, H_1)$ can be derived from $f_p(p | \eta, H_1)$ with a change of variables. In principle, minimum Bayes factors can also be considered for data-based Bayes factors, but the computation may be cumbersome if the distribution $f(y | H_1)$ depends on many unknown parameters.

The minimum Bayes factor is the smallest possible Bayes factor that can be obtained for a p-value p in a certain class of distributions considered under the alternative. As such, it provides an objective lower bound on the Bayes factor, an objective Bayes procedure (Berger 2006). Note that minimum Bayes factors have the same asymmetry as p-values, as they can be used only to assess the (maximal) evidence against H_0 , not for H_0 . Examples of p-based minimum Bayes factors are given in Section 2.3. Incidentally, the corresponding maximum Bayes factor usually does not exist, since the marginal likelihood under the alternative does not have a strictly positive minimum for continuous distributions. This is illustrated in the example described in Section 1.3.1 and **Figure 1**.

1.3. Examples

We now describe two clinical applications where a Bayesian calibration of p-values is of interest. The first example describes a well-designed confirmatory study, where a single p-value is available for the primary outcome of interest. In the second example, many exploratory p-values are available from a logistic regression analysis with many potential predictors. Exploratory p-values are to be understood as summary statistics of the data only and should not be used for decision making, but they can be used for generating hypotheses. The distinction between confirmatory and exploratory p-values is important (Tukey 1980, Berry 2016, Matthews et al. 2017) and requires different methods for a Bayesian calibration via minimum Bayes factors. We argue that simple alternatives are suitable for confirmatory p-values, whereas local alternatives should be used for exploratory p-values.

1.3.1. Confirmatory *p***-values.** Imagine a randomized controlled clinical trial designed to detect a prespecified clinically relevant difference with 80% power ($\beta = 0.2$) at the usual two-sided 5% significance level ($\alpha = 0.05$). A two-sided *p*-value p = 0.01 has been reported for the null hypothesis H_0 of no difference between the two treatments. The principal investigator (PI) of the trial knows that the *p*-value is only an indirect measure of the evidence against H_0 and has read much of the recent literature on misinterpretations and problems with *p*-values. He therefore asks

Test-based Bayes factor: a Bayes factor that is based on the sampling distributions of a test statistic

Minimum Bayes factor: the smallest possible Bayes factor within a prespecified class of prior distributions over alternative hypotheses

6.




Figure 1

The Bayes factor (Equation 8) as a function of the mean μ for absolute test statistic $t^* = 0.67$, 1.64, 2.58, and 3.29 (p = 0.5, 0.1, 0.01, and 0.001). The minima at $\hat{\mu}_{ML} = 0$, 1.63, 2.58, and 3.29, the values of μ that maximize $f(t^* | H_1)$, are marked with colored squares and correspond to minimum Bayes factors of 1, 1/1.9, 1/14, and 1/112. Based on the sample size calculations, we have $\mu = 2.80$ (*dashed gray line*) with Bayes factors of 15, 1, 1/13, and 1/100 (*black dots*).

the trial statistician to compute a Bayes factor as a direct measure of the evidence against the null. The statistician has calculated p based on a test statistic t which follows—for sufficiently large sample size—a standard normal distribution if H_0 is true. He has also derived the distribution of t under the assumption of the alternative $H_1: t \sim N(\mu, 1)$ (Matthews 2006, section 3.3) with

$$\mu = \Phi^{-1}(1 - \alpha/2) + \Phi^{-1}(1 - \beta), \qquad 7.$$

where $\Phi(.)$ denotes the standard normal cumulative distribution function. However, the two-sided *p*-value $p = 2 [1 - \Phi(|t|)]$ is not a one-to-one function of *t*, but it is a one-to-one function of the absolute value of *t*. With a change of variables to the folded normal random variable $t^* = |t|$ (see Appendix A.1 for its density function), the Bayes factor (Equation 5) is then

$$BF(t^*) = \frac{f(t^* \mid H_0)}{f(t^* \mid H_1)} = \frac{2\varphi(t^*)}{\varphi(t^* + \mu) + \varphi(t^* - \mu)},$$
8.

where $\varphi(.)$ denotes the standard normal probability density function (pdf) and

$$t^* = t^*(p) = \Phi^{-1}(1 - p/2).$$
 9.

The trial statistician obtains $\mu = 2.80$ from Equation 7 with $\alpha = 0.05$ and $\beta = 0.2$, $t^* = 2.58$ from Equation 9 with p = 0.01, and finally, BF(p = 0.01) = 1/13 (0.0744) from Equation 8. He concludes that there is substantial evidence against H_0 since the probability of no effect has decreased from 50% (his prior guess) to 0.0744/(1 + 0.0744) = 6.9%.

However, the statistician is well aware that the assumptions underlying the sample size calculations may not be true. In particular, the power of the study may have been different from the assumed $1 - \beta$ value if the true treatment effect is different from the prespecified effect. He therefore minimizes Equation 8 numerically with respect to μ (for fixed $t^* = 2.58$) and obtains a lower bound minBF(p) on the Bayes factor, which turns out to be minBF(p) = 1/14(0.0725) with a corresponding lower bound of 6.8% for Pr($H_0 | p$).

The step from the Bayes factor (Equation 8) to the minimum Bayes factor

$$\min BF(t^*) = \min_{u} \{BF(t^*)\}$$
10.

can be done for any value of t^* , and hence for any *p*-value, as illustrated in **Figure 1**. Note that for $\mu = 0$, we have BF(t^*) = 1 for any value of t^* . The other extreme is $\mu \to \infty$, where BF(t^*) $\to \infty$, again for any t^* , so this Bayes factor has no maximum. Between these two extremes, there is a minimum of BF(t^*). For moderately large t^* , say $t^* \ge 1.64$, the minimum is near $\mu = t^*$ (compare with **Figure 1**). If $t^* \le 1$, i.e., $p \ge 0.32$, the minimum is at $\mu = 0$ and minBF(t^*) = 1 (Berger & Sellke 1987, section 3.3).

Similar results can be obtained if the *p*-value p = 0.01 is one-sided for the alternative H_1 : $\mu > 0$. To see this, note that the Bayes factor now is

$$BF(t) = \frac{f(t \mid H_0)}{f(t \mid H_1)} = \frac{\varphi(t)}{\varphi(t - \mu)},$$
11.

where $t = \Phi^{-1}(1-p) = 2.33$. This leads to BF(t) = 1/13 (0.0748) and minBF(t) = 1/15 (0.0668).

So far, so good. But a colleague of the trial statistician notes that simpler procedures to compute a minimum Bayes factor based on a *p*-value have been proposed in the literature. Specifically, he mentions the $-ep \log p$ calibration (Sellke et al. 2001), which has been reported to provide the lowest Bayes factor against H_1 under reasonable assumptions (Bayarri et al. 2016). But surprisingly, for p = 0.01, this calibration gives a considerably larger minimum Bayes factor of 1/8 (0.125) than the Bayes factor 1/13 the statistician has obtained. The assumptions underlying the sample size calculations have been thoroughly prepared and have been considered realistic by the PI and the ethics committee approving the trial protocol, so how can a lower bound on all reasonable Bayes factors be larger than his Bayes factor?

In fact, the $-ep \log p$ calibration closely agrees with the lower bound for local alternatives but not for simple alternatives. The colleague thus points him to another calibration advocated by Goodman (1999b), who proposed the lower bound $\exp(-t^2/2)$ for the Bayes factor, where $|t| = t^*$ as in Equation 9. This bound turns out to be 1/28 for p = 0.01, so it is half as large as the lower bound 1/14 he has obtained. This seems overly conservative to the trial statistician, and he is now completely confused and unsure what Bayes factor he should report to the PI. We see in Section 2.1 that the Goodman (1999b) bound, just as the minimum Bayes factor given by Equation 10, is based on a simple alternative but incorporates additional knowledge on the direction of the effect.

1.3.2. Exploratory *p*-values. Many statistical procedures produce not just one *p*-value, but a large number of them. For example, multiple regression is often used to develop clinical prediction models and gives a *p*-value for each potential predictor. For illustration, we consider the development of a clinical prediction model for 30-day survival after acute myocardial infarction in Section 4.2.2. The set of potential predictors consists of 17 covariates. A first step to assess the importance of each of the predictors is to report 17 exploratory *p*-values in a standard regression table of the full model with all covariates. We describe in Section 4.2 how such a table can be accompanied with the corresponding minimum Bayes factors. This analysis is exploratory in nature since the study was not powered for any of the potential predictors (treatment is not included), so we have a set-up where local alternatives should be used to calculate minimum Bayes factors.

1.4. Overview of Article

In this article we provide a comprehensive overview of different methods to transform *p*-values to minimum Bayes factors, with an emphasis on two-sided *p*-based and test-based Bayes factors.

We make the important distinction between simple and local alternatives, the latter class implying more restrictive assumptions, leading to larger minimum Bayes factors.

We start with a historical review in Section 2, where we describe the literature on data-based and *p*-based Bayes factors, as well as the more recent framework of test-based Bayes factors. The dependence of minimum Bayes factors on the sample size is described in Section 3. We see that the maximal evidence of a *p*-value is inversely related to sample size. Test-based Bayes factors allow investigation of the dependence of the minimum Bayes factor on the dimension of θ (Section 4) and that minimum Bayes factor can be used to assess the combined evidence of multiple *p*-values (Section 4.3). We close with some discussion in Section 5, and some mathematical results are presented in the Appendix. All calibrations of *p*-values as minimum Bayes factors discussed in this article are implemented in the R-package pCalibrate available on the Comprehensive R Archive Network (https://CRAN.R-project.org/package=pCalibrate).

2. HISTORICAL REVIEW

Jeffreys (1961, appendix B) already studied the relationship between *p*-values and (approximate) Bayes factors for normally and binomially distributed observations (see also Berger & Sellke (1987) for more information on the normal case). One of the first papers with a systematic comparison of *p*-values and the corresponding minimum Bayes factors was published in the 1960s (Edwards et al. 1963), and is considered as "still one of the best technical introductions to the Bayesian philosophy" (Spiegelhalter et al. 2004, p. 115).

2.1. Simple Alternatives

Edwards et al. (1963, p. 226) "examine one situation in which classical statistics prescribes a [...] *t* test," but in fact consider what is usually called a *z*-test for large samples (Bland 2015, section 9.7). Specifically, the authors consider the problem of testing the point null hypothesis H_0 : $\theta = \theta_0$ for a normally distributed observation $y \sim N(\theta, \sigma^2)$ with mean θ and known variance σ^2 . In practice the observation *y* is a sufficient statistic for the parameter of interest, for example, an average or a maximum likelihood estimate. The normality assumption underlies many statistical procedures found in medical journals (Goodman 1999b) and also in other areas of quantitative research. Let *t* denote the value of the test statistic $t = (y - \theta_0)/\sigma$. Edwards et al. (1963) observed that—for all possible prior densities $f(\theta | H_1)$ on θ under H_1 —the Bayes factor for H_0 against H_1 , BF(y) = $f(y | H_0)/f(y | H_1)$, has the lower bound

$$\min BF(y) = \exp(-t^2/2),$$
 12.

the minimum Bayes factor in the class of all possible prior distributions for θ . They also noted that the minimum is attained if "the density under the alternative hypothesis is concentrated at y, the place most favored by the data" (Edwards et al. 1963, p. 228), i.e., for the simple alternative $H_1: \theta = \theta_1 = y$.

Note that the minimum Bayes factor in Equation 12 is just a function of the test statistic t and that the corresponding test-based Bayes factor BF(t) = $f(t | H_0)/f(t | H_1)$ based on $t | H_0 \sim N(0, 1)$ and $t | H_1 \sim N(\mu, 1)$ leads to the very same result, i.e., $\min_{\mu} BF(t) = \min BF(y)$. It is often the case that a test-based Bayes factor is equal to the corresponding data-based Bayes factor if the test statistic and prior distributions have been chosen carefully.

However, it is not clear how a *p*-value *p* should be transformed to the test statistic *t*. Edwards et al. (1963, p. 228) restrict attention to one-sided *p*-values ($p \le 0.5$) and use the corresponding one-sided *t*-value $t = \Phi^{-1}(1 - p)$ in Equation 12. This approach is based on the argument that "the alternative hypothesis has all its density on one side of the null hypothesis, [so] it is perhaps

appropriate to compare the outcome of this procedure with the outcome of a one-tailed rather than a two-tailed classical test." We see in Section 4.2.2 that the Edwards bound also provides a sharp lower bound on the Bayes factor under specific local alternatives, so-called g-priors, for parameter vectors of any dimension.

In contrast, Goodman (1999b, p. 1007) recommended applying Equation 12 to two-sided *p*-values to obtain the "smallest possible Bayes factor." The problem with this approach is that the test statistic *t* in Equation 12 is not a one-to-one function of the two-sided *p*-value $p = 2[1-\Phi(|t|)]$. Therefore the minimum Bayes factor based on *t* (Equation 12) is not the same as the minimum Bayes factor for the corresponding *p*-value *p*, since the former uses the additional information on the direction of the treatment effect, represented by the sign of *t*. The Goodman approach is therefore best seen as the Edwards bound applied to the corresponding one-sided *p*-value *p*/2, so that the information about the direction of the effect is included.

We described in Section 1.3.1 how the absolute test statistic $t^* = |t|$ is a one-to-one function of p and the Bayes factor based on t^* (Equation 8) can be used to calculate the minimum Bayes factor under a simple alternative (Equation 10), numerically minimizing Equation 8 with respect to μ . This approach is equivalent to requiring the prior densities $f(\theta | H_1)$ to be symmetric (but possibly non-local) around θ_0 , as described by Berger & Sellke (1987, section 3.3). For two-sided p-values smaller than 0.1(so $t^* > 1.64$), the minimum Bayes factor (Equation 10) can be well approximated as

minBF(
$$t^*$$
) $\approx \frac{2\varphi(t^*)}{\varphi(2\,t^*) + \varphi(0)} \approx 2\exp(-t^{*2}/2)$ 13.

(the exact multiplier on the right-hand side of Equation 13 is then between 1.99 and 2.0 rather than exactly 2). Comparing Equation 13 with Equation 12 we see that, for sufficiently small *p*-values, the Goodman (1999b) proposal is by a factor of 2 too small, and this is exactly what we have observed in the example considered in Section 1.3.1.

2.2. Local Alternatives

Another important case considered by Edwards et al. (1963) is a local normal prior for the mean θ of $y \sim N(\theta, \sigma^2)$, centered around the null value $\theta_0: \theta \mid H_1 \sim N(\theta_0, \tau^2)$. This specification is appropriate for exploratory *p*-values from observational or hypothesis-generating studies, where no specific alternative hypothesis has been specified a priori. It is shown that in this case the minimum Bayes factor (minimized with respect to τ^2 , which yields $\tau^2 = \sigma^2 \max\{t^2 - 1, 0\}$) is

$$\min BF(y) = \begin{cases} |t| \exp(-t^2/2)\sqrt{e} & \text{for } |t| > 1\\ 1 & \text{otherwise,} \end{cases}$$
 14.

and here $e \approx 2.72$ is Euler's number. Note that this bound also depends on the data only through the absolute value $t^* = |t|$ of the test statistic t. It is easy to show that we get the same result if we use the test-based Bayes factor based on t^* , where t^* has a folded normal distribution with mean 0 and variance 1 under H_0 , and it has a folded normal distribution with mean 0 and variance $1 + \tau^2/\sigma^2$ under H_1 . Since the prior on θ under H_1 is centered around the null value θ_0 , t^* has mean 0 under H_1 and it is easy to check that calculating the Bayes factor using t instead of t^* , with $t \mid H_0 \sim N(0, 1)$ and $t \mid H_1 \sim N(0, 1 + \tau^2/\sigma^2)$, also leads to the same result. This is in contrast to the setting for the bound given by Equation 12, where the mean of t^* under H_1 is nonzero and the Bayes factors based on t and t^* , respectively, differ. The local normal alternatives bound (Equation 14) is substantially larger than the Edwards bound (Equation 12); see Section 2.5.

We note that the more general class of all (possibly nonnormal) local alternatives has been considered by Berger & Sellke (1987, section 3.4). The resulting minimum Bayes factors are only

Folded normal distribution: the distribution of the absolute value of a normally distributed random variable slightly smaller than the ones obtained in the class of local normal priors. Local normal priors have the advantage that they can more easily be generalized to *g*-priors to investigate situations where the parameter of interest is a vector; see Sections 3.2 and 4.2.2.

2.3. *p*-Based Bayes Factors

The minimum Bayes factors given by Equations 12 and 14 depend on the value of the *t*-statistic *t*, so they only depend indirectly on the *p*-value *p*. The commonly used $-e p \log p$ calibration, proposed by Vovk (1993, Section 9) and Sellke et al. (2001), depends directly on the *p*-value *p*:

$$\min BF(p) = \begin{cases} -e \ p \log p & \text{for } p < 1/e \\ 1 & \text{otherwise.} \end{cases}$$
15.

A simple derivation of Equation 15 assumes that under a point null hypothesis H_0 , an exact *p*-value *p* is uniformly distributed on the unit interval. Under the alternative hypothesis, small *p*-values are expected, so the class of beta prior distributions Be(ξ , 1) with monotonically decreasing density functions ($\xi \leq 1$) is considered.

The minimum Bayes factor (Equation 15) can then be derived as described by Sellke et al. (2001) and Held & Ott (2016, appendix B), using the maximum likelihood estimate (MLE) $\hat{\xi}_{ML} = \min\{-1/\log(p), 1\}$. Sellke et al. (2001) also present an alternative derivation of Equation 15, in which one does not have to assume the beta class for the *p*-value under H_1 . Held (2010) noted that Equation 15 can also be derived as a test-based Bayes factor under the *g*-prior if θ has dimension 2 and the sample size is large; see Section 4.2.2 for details. The calibration given by Equation 15 is always smaller than the local normal alternatives bound (Equation 14) and approximately equal to the lower bound in the more general class of all local alternatives (Sellke et al. 2001, section 3.2).

The beta distribution $Be(\xi, 1)$ with $\xi \leq 1$ has prior sample size $\xi + 1 \leq 2$, so it is always quite uninformative. Therefore, $f(p | H_1, \hat{\xi}_{ML})$ will be relatively flat, and the minimum Bayes factor minBF $(p) = 1/f(p | H_1, \hat{\xi}_{ML})$ will be relatively large. However, this is not the only class of beta priors with monotonically decreasing density functions. An alternative, which to our knowledge has not yet been discussed in the literature, is the class of beta distributions Be $(1, \kappa)$ with $\kappa \geq 1$. A beta distribution from this class has prior sample size $1 + \kappa \geq 2$, so the likelihood under the alternative can take larger values than for the above Be $(\xi, 1)$ prior. Calculus shows that in this setting, the MLE of κ is $\hat{\kappa}_{ML} = \max\{-1/\log(1-p), 1\}$, leading to the minimum Bayes factor

$$\min BF(p) = \begin{cases} -e (1-p)\log(1-p) & \text{for } p < 1-1/e \\ 1 & \text{otherwise.} \end{cases}$$
16.

This is similar to the $-e p \log p$ calibration, but with p replaced by q = 1 - p, so we call this the $-e q \log q$ calibration. Note that for small enough p we can obtain the simple approximate formula minBF(p) $\approx e p$ based on the approximation $\log(1 - p) \approx -p$.

It turns out that Equation 16 is a much lower bound compared with all the other bounds proposed. For *p*-values less than 0.1 it is even smaller than the Goodman approach; Section 2.5 provides a comparison. This is due to a large (and unbounded) prior sample size for small *p*, in contrast to the prior sample size of the $-e p \log p$ calibration, which cannot be larger than 2. However, we will see in Section 3.2 that Equation 16 provides a sharp lower bound on Bayes factors based on *g*-priors of any dimension *d*, even if the sample size is very small. For reasonably large sample sizes, however, the $-e q \log q$ calibration will be too conservative.

Prior sample size: the weight attached to a prior distribution, expressed as the equivalent sample size

2.4. Test-Based Bayes Factors

A drawback of data-based Bayes factors is that their values often depend critically on prior distributions that are assigned to unknown parameters under the null hypothesis and the alternative (Johnson 2005). Furthermore, computation of these Bayes factors may be involved as multidimensional integrals may need to be evaluated. In a landmark paper, Johnson (2005) proposes Bayes factors based on test statistics instead of the original data to facilitate the use of Bayes factors. To obtain these Bayes factors, he considers the sampling distribution of the test statistic under the null and the alternative hypothesis. Usually, the distribution under the null does not depend on unknown model parameters, and the distribution under the alternative can be parameterized in a parsimonious way-often as a noncentral version of the distribution under the null hypothesis with only one additional noncentrality parameter; see Section 4.2 for an example. Thus, his approach eliminates the need to specify prior distributions for all unknown model parameters under each hypothesis and thus much of the subjectivity associated with Bayes factors. For several commonly used test statistics, he obtains a simple closed-form expression for the test-based Bayes factor assuming a computationally convenient prior for the noncentrality parameter. These results significantly simplify computation of Bayes factors. He considers χ^2 -, F-, t- and z-test statistics in Johnson (2005) and extends the approach to likelihood ratio test (deviance) statistics in Johnson (2008), which allows for application of the methodology to generalized linear models (GLMs).

We describe test-based Bayes factors based on the F-statistic in Section 3 and test-based Bayes factors based on the deviance in Section 4.2. A Bayesian model selection algorithm using test-based Bayes factors for linear models and GLMs is proposed in Hu & Johnson (2009). Held et al. (2015) show that Bayes factors based on the deviance statistic approximate data-based Bayes factors in GLMs and relate minimum test-based Bayes factors to minimum Bayes factors from the literature. There is also literature on Bayes factors based on nonparametric test statistics (Yuan & Johnson 2008). Bayes factors based on the deviance are applied to the Cox proportional hazard model in Held et al. (2016).

2.5. A Comparison

Edwards et al. (1963) compare *p*-values of 0.05, 0.01, and 0.001 with a selection of minimum Bayes factors. **Table 3** provides a similar list with the minimum Bayes factors discussed so far, using the additional *p*-value p = 0.005—recently proposed by Benjamin et al. (2017) as a new threshold for statistical significance—and our preferred formatting of Bayes factors as ratios. First, note that all the minimum Bayes factors are substantially larger than the corresponding *p*-values and that the simple alternative minimum Bayes factor is always twice as large as the Goodman lower bound.

<i>p</i> -value		0.05	0.01	0.005	0.001
Minimum Bayes factor	Formula				
Local normal alternatives	Equation 14	1/2.1	1/6.5	1/11	1/41
$-e p \log p$	Equation 15	1/2.5	1/8	1/14	1/53
Simple alternative	Equation 10	1/3.4	1/14	1/26	1/112
Edwards	Equation 12, one-sided	1/3.9	1/15	1/28	1/118
Goodman	Equation 12, two-sided	1/6.8	1/28	1/51	1/224
$-e q \log q$	Equation 16	1/7.5	1/37	1/74	1/368

 Table 3
 Comparison of *p*-values and various minimum Bayes factors

Table inspired by table 4 in Edwards et al. (1963).

Furthermore, the Edwards bound is close but not equal to the simple alternative minimum Bayes factor. Also observe that the Goodman minimum Bayes factor for two-sided p = 0.01 is the same as the Edwards minimum Bayes factor for one-sided p = 0.005. The $-e p \log p$ bound is close to the minimum Bayes factor under local normal alternatives. The $-e q \log q$ bound is smaller than all the other minimum Bayes factors, even smaller than the Goodman bound.

3. SAMPLE-SIZE ADJUSTED BAYES FACTORS

It is well known that data-based Bayes factors depend on the sample size. By using Bayes factor methodology, several researchers have shown that the evidence of a *p*-value also depends on the underlying sample size (Jeffreys 1961, Royall 1986, Spiegelhalter et al. 2004, Wagenmakers 2007). In contrast, the *p*-based calibrations in Section 2.3 transform a given *p*-value to the same minimum Bayes factor no matter what the underlying sample size is. The same is true for the calibrations introduced in Sections 2.1 and 2.2 if the transformation from the *p*-value to the test statistic is based on the quantiles of the (folded) normal distribution as described in those sections. However, the (folded) normal distribution is often only the asymptotic distribution of the test statistic. For small samples, such approximations should be avoided and the underlying sample size should be taken into account when transforming the *p*-value to the test-statistic and then to the minimum Bayes factor. Held & Ott (2016) proposed such sample-size adjusted minimum Bayes factors for two-sided *p*-values from the *t*-test and *F*-test.

We now describe the dependence of the minimum Bayes factors on sample size in several settings. In Section 3.1, we consider the *t*-test and the *F*-test in the linear model under simple alternatives. In Section 3.2, we study a class of local alternatives in the linear model, so-called *g*-priors, as in Held & Ott (2016).

3.1. Simple Alternatives

Let us revisit the motivating example from Section 1.3.1, which was based on a normal test statistic where a Bayes factor of BF(p = 0.01) = 1/13 (0.0744) with corresponding lower bound of 1/14 (0.0725) was obtained. A normal assumption is appropriate for large sample sizes, but suppose now that the sample size n of the study was fairly small, with only 10 patients in each group, so n = 20. Assume that the *p*-value p = 0.01 was obtained from the corresponding two-sample *t*-test with n - 2 degrees of freedom. The Bayes factor then has the form

$$BF(t^*) = \frac{2f_{t(n-2)}(t^*)}{f_{t(n-2)}(t^* + \mu) + f_{t(n-2)}(t^* - \mu)},$$
17.

where $f_{t(d)}(.)$ denotes the pdf of a standard *t* distribution with *d* degrees of freedom, and $t^* = t^*(p)$ is now the (1 - p/2)-quantile of the standard *t* distribution with n - 2 degrees of freedom. Note that μ is computed as in Equation 7, but with the standard *t* replacing the standard normal pdf at both occurrences. As in Section 1.3.1, we can minimize Equation 17 with respect to μ to obtain the corresponding minimum Bayes factor

$$\min BF(t^*) = \min \left\{ BF(t^*) \right\}$$
18.

under a simple alternative. The resulting Bayes factor (Equation 17), with $\mu = 2.96$, n = 20, and $t^*(p = 0.01) = 2.88$, is BF($t^* = 2.88$) = 1/18 (0.0550), so it is somewhat smaller than that for a large sample size with a lower bound of minBF($t^* = 2.88$) = 1/18 (0.0548). This suggests that *p*-values obtained from small studies may carry more (maximal) evidence against the null hypothesis




Figure 2

Bayes factors (a) with $\mu = 2.96$ and (b) minimum Bayes factors for a simple alternative as a function of the *p*-value from a *t*-test. Shown are the results for different sample sizes *n*.

than the very same *p*-values from larger studies, but this is only true for minimum Bayes factors, not for Bayes factors.

Indeed, **Figure 2***a* illustrates that the Bayes factor given by Equation 17 with fixed $\mu = 2.96$ of a small study can be larger than the Bayes factor of a larger study, for small enough *p*-values. Spiegelhalter et al. (2004, section 4.4.3) also observe a similar nonmonotonic relationship of Bayes factors and sample size *n* for fixed *p*-values assuming a random sample of size *n* from a normal distribution and a local (normal) prior on the mean. In contrast, the minimum Bayes factor shown in **Figure 2***b* decreases monotonically with decreasing sample size for any *p*-value.

If the *p*-value p = 0.01 in the motivating example had been one-sided for the alternative H_1 : $\mu > 0$, then a sample-size adjusted modification of the large-sample Bayes factor (Equation 11) would be BF(*t*) = $f_{t(n-2)}(t)/f_{t(n-2)}(t-\mu)$, where the *t*-value *t* is now the (1 - p)-quantile of the standard *t* distribution with n - 2 degrees of freedom. For $\mu = 2.96$, n = 20, and t(p = 0.01) =2.55, this Bayes factor is BF(*t*) = 1/17 (0.0581), which is similar to the value of the Bayes factor for the two-sided *p*-value (Equation 17) obtained above. The corresponding minimum Bayes factor

minBF(t) = min
$$\frac{f_{t(n-2)}(t)}{f_{t(n-2)}(t-\mu)} = \left(1 + \frac{t^2}{n-2}\right)^{-(n-1)/2}$$
 19

turns out to be minBF(t) = 1/19 (0.0532), so it is only slightly smaller than the minimum Bayes factor for the two-sided case (Equation 18). It is true in general that for the same large-enough p-value (the threshold depending on the sample size n), the minimum Bayes factor given by Equation 19 is smaller than the one given by Equation 18. For smaller p-values, these two minimum Bayes factors are very similar. Furthermore, the minimum Bayes factor given by Equation 19 also decreases with decreasing sample size n for a fixed one-sided p-value from the t-test, so we observe the same dependence on n as for the two-sided t-test p-values.

In the following, we derive the Bayes factor for the *F*-test of overall significance in the standard linear regression model with intercept α ,

$$y = \alpha \mathbf{1} + \mathbf{X}\boldsymbol{\theta} + \boldsymbol{\epsilon}, \qquad 20.$$

g-**Prior**: a normal prior distribution with mean zero and covariance matrix proportional to the inverse Fisher information matrix of the regression coefficients

where the response vector
$$y$$
 is of length n , the regression coefficient vector θ is of dimension $d \leq n-2$, the design matrix **X** has dimension $n \times d$, and the errors in ϵ are assumed to be independent and normally distributed with zero mean and unknown residual variance σ^2 . The *F*-statistic is then given as

$$f = \frac{R^2/d}{(1-R^2)/(n-d-1)},$$
21.

where R^2 is the usual coefficient of determination, the proportion of the variance in the response variable *y* that can be explained from the explanatory variables **X**.

Under the null hypothesis $H_0: \theta = 0$, the *F*-statistic (Equation 21) has a central *F* distribution with *d* and n-d-1 degrees of freedom, which is used to calculate the associated *p*-value, the upper tail probability at the observed *F*-value. Under the alternative $H_1: \theta = \theta_1$, *f* has a noncentral *F* distribution with *d* and n-d-1 degrees of freedom and noncentrality parameter λ . The resulting Bayes factor BF(*f*) can then be minimized with respect to the noncentrality parameter λ .

3.2. Local g-Priors

We now outline the derivation of a minimum test-based Bayes factor based on the *F*-statistic and local *g*-priors, as given by Johnson (2005). Suppose now we want to test the above null hypothesis $H_0: \theta = \mathbf{0}$ against the composite alternative $H_1: \theta \neq \mathbf{0}$. It is typically easier to assign a prior to the vector of regression coefficients θ under H_1 than to the noncentrality parameter λ ; the prior on θ will then imply a prior on λ . In the absence of substantive prior information, it is common to assign the *g*-prior (Zellner 1986)

$$\boldsymbol{\theta} \mid \sigma^2, H_1 \sim \mathrm{N}(\mathbf{0}, g \, \sigma^2 \, (\mathbf{X}^T \, \mathbf{X})^{-1})$$
 22.

for fixed g > 0 to θ , which is invariant with respect to location-scale transformations of the covariates (Bayarri et al. 2012).

Note that the *g*-prior is a local prior for $H_0: \theta = \mathbf{0}$ with a covariance matrix proportional to the inverse Fisher information matrix $\sigma^2 (\mathbf{X}^T \mathbf{X})^{-1}$ of the regression coefficients θ . It reduces to the normal prior described in Section 2.2 (for $\theta_0 = 0$) if θ is a scalar and σ^2 is known.

For the following, no additional prior distribution on σ^2 is required since the prior distribution on λ implied by the *g*-prior (Equation 22) does not depend on σ^2 [we have $\lambda/g \sim \chi^2(d)$]. By integrating out λ , one deduces that, under H_1 , f/(1 + g) has a central *F* distribution with *d* and n - d - 1 degrees of freedom. The corresponding test-based Bayes factor turns out to be

BF(f) =
$$(g+1)^{-(n-d-1)/2} \left\{ 1 + g \left[1 - \frac{f}{f + (n-d-1)/d} \right] \right\}^{(n-1)/2}$$
. 23.

Interestingly, this test-based Bayes factor (Equation 23) is equal to the data-based Bayes factor BF(y) for the linear model (Equation 20) obtained under the g-prior (Equation 22) on $\theta | \sigma^2$ combined with a reference prior $f(\alpha, \sigma^2) \propto \sigma^{-2}$ for the intercept α and the residual variance σ^2 , as given by Liang et al. (2008). In particular, the data-based Bayes factor BF(y) depends on the data only through the *F*-statistic (Equation 21), the sample size *n*, and the dimension *d* of θ . The Bayes factor given by Equation 23 can actually be derived under more general assumptions, where the null hypothesis is a linear constraint on the parameter vector θ , for example, the null hypothesis that a single component of θ is zero (Johnson 2005).

Note that BF(f) = 1 for g = 0 and $BF(f) \to \infty$ for $g \to \infty$. The first result is obvious, as the Bayes factor then compares two identical models. The second result is related to the Jeffreys-Lindley paradox (Lindley 1957, Jeffreys 1961), which states that for large prior variances, the Bayes factor always prefers the simpler model, no matter what the data are. In between, there is




Figure 3

The dependence of the minimum Bayes factors under (*a*) a simple alternative (Equation 18) and (*b*) local alternatives (Equation 24 with d = 1) on sample size for a fixed two-sided *p*-value from a *t*-test.

a unique minimum of Equation 23 for $\hat{g}_{ML} = \max \{f - 1, 0\}$. By inserting the MLE \hat{g}_{ML} into the Bayes factor (Equation 23), we obtain the minimum Bayes factor

$$\min_{g} BF(f) = \min_{g} BF(f) = \begin{cases} \left[\frac{1+(n-d-1)/d}{f+(n-d-1)/d}\right]^{(n-1)/2} f^{d/2} & \text{for } f > 1\\ 1 & \text{otherwise.} \end{cases}$$
 24.

Note that this formula only depends on f, n, and d, so it provides a convenient way to transform an F-statistic (or the corresponding p-value) to a lower bound on the Bayes factor.

Held & Ott (2016) studied the relationship between a *p*-value from the *F*-test and the corresponding minimum Bayes factor given by Equation 24. Their main findings were as follows:

- 1. For fixed *p* and fixed dimension *d*, the minimum Bayes factor (Equation 24) decreases with decreasing sample size *n*.
- 2. For fixed *p* and fixed sample size *n*, the minimum Bayes factor (Equation 24) decreases with increasing dimension *d*.

Figure 3 compares the minimum Bayes factor based on the local *g*-prior (Equation 24) for d = 1 with the minimum Bayes factor based on simple alternatives (Equation 18) for fixed *p*-value and varying sample size *n*. We see the same pattern in both cases, with increasing minimum Bayes factors for increasing sample size.

In **Figure 4** we show the dependence of the minimum Bayes factor given by Equation 24 on the *p*-value for d = 3 and d = 4 and different sample sizes *n*; Held & Ott (2016) give the corresponding plots for d = 1 and d = 2. We have added the $-e p \log p$ bound (Equation 15) as a blue line, which is always larger than the sample-size adjusted minimum Bayes factors. We have also added the $-e q \log q$ bound (Equation 16) as a red line, which is always below the sample-size adjusted minimum Bayes factors.

As a consequence of the Held & Ott (2016) results, the minimum Bayes factor given by Equation 24 is largest for d = 1 and large n. As we see in Section 4, the value of the minimum Bayes factor in fact converges for $n \to \infty$ to the local normal alternatives bound (Equation 14) with




Figure 4

Minimum Bayes factors based on local *g*-priors (Equation 24) as a function of the *p*-value from an *F*-test. Shown are the bounds for (*a*) d = 3 and (*b*) d = 4 for sample size n = d + 3, 10, 20 and for when *n* is large. The blue line is the $-e p \log p$ calibration (Equation 15), and the red line is the $-e q \log q$ calibration (Equation 16).

 $t^* = \sqrt{f}$. The minimum Bayes factor (Equation 24) is smallest for large *d* and small *n*. Standard regularity conditions in the linear model require $n \ge d+2$, and we now consider the case n = d+3, where $f \mid H_0 \sim F(d, 2)$. The quantile function of $f \mid H_0$ is then available in closed form (see Equation 34 in Section A.2.1), and there is a closed-form expression for the minimum Bayes factor (Equation 24) as a function of the *p*-value *p*:

minBF(p) =
$$(d+2) \frac{1-(1-p)^{2/d}}{2} \left(\frac{d+2}{d}\right)^{d/2} (1-p),$$
 25.

as derived in the Appendix (Section A.2.1). We show in Section A.2.1 that the limit of Equation 25 for $d \to \infty$ is the $-e q \log q$ calibration (Equation 16). Since the convergence is from above, the $-e q \log q$ calibration (Equation 16) is a universal lower bound on sample-size adjusted minimum Bayes factors based on local *g*-priors, if we exclude the very extreme case n = d + 2, where the minimum Bayes factor can be even smaller than the bound given by Equation 16.

Another interesting special case of the minimum Bayes factor based on the *F*-statistic (Equation 24) can be obtained for d = 2. In this case, there is a closed-form relationship between the *p*-value from the *F*-test and the *F*-statistic (Held & Ott 2016, equation 11), so Equation 24 can be rewritten as a *p*-based Bayes factor:

minBF(p) =
$$\frac{1}{2} \left[\frac{(n-1)^{(n-1)}}{(n-3)^{(n-3)}} \right]^{1/2} \left[1 - p^{2/(n-3)} \right] p$$
 26.

$$\approx \frac{e}{2}(n-2) \left[1-p^{2/(n-3)}\right] p$$
 27.

for $p < (\frac{n-1}{n-3})^{-(n-3)/2}$; otherwise minBF(p) = 1. Held & Ott (2016) show that for fixed n, Equation 26 is always smaller than the $-e p \log p$ calibration (Equation 15) and that Equation 27 converges from below to Equation 15 for $n \to \infty$. However, it has been argued that the $-e p \log p$ calibration (Equation 15) already provides a (lower) bound on the Bayes factor "under general

assumptions" (Stephens & Balding 2009, p. 684) and constitutes "a best-case scenario for the strength of the evidence in favor of H_1 that can arise from a given *p*-value" (Bayarri et al. 2016, p. 91). This is not true for *g*-priors, as our analysis has shown. As illustrated in **Figure 4**, the minimum Bayes factor (Equation 24) is always smaller than Equation 15 for any $d \ge 2$ and any finite sample size. Even for d = 1, the standard *t*-test setting, the $-e p \log p$ calibration (Equation 15) can be larger than Equation 24 if *n* is small. For example, for *p*-values not smaller than 10^{-4} , the sample size must be n = 27 or larger, such that Equation 15 is a valid bound. For *p*-values not smaller than 10^{-6} , the sample size must be n = 37 or larger for Equation 15 to be valid.

4. LARGE-SAMPLE BAYES FACTORS

We saw in Section 3 that the (approximate) minimum Bayes factor given by Equation 27 converges to the $-e p \log p$ calibration (Equation 15) for $n \to \infty$. We now generalize that result by establishing convergence of the minimum Bayes factor given by Equation 24 to a test-based Bayes factor based on the deviance for general *d*. We will also provide an alternative derivation of that test-based Bayes factor in the GLM framework and analyze its dependence on *d*.

4.1. Some Convergence Results

It is easy to see that the Bayes factor given by Equation 17 converges to the Bayes factor given by Equation 8 as the sample size *n* goes to infinity, since the absolute value $t^* = |t|$ of the *t*-statistic converges to the quantile in Equation 9 and the *t*-density in Equation 17 converges to the standard normal density as the degrees of freedom go to infinity.

Next, we study the Bayes factor based on the *F*-statistic (Equation 23), which was derived under the *g*-prior, as the sample size *n* goes to infinity. To do so, we assume a sequence of alternatives of the form $H_1^n: \theta = O(n^{-1/2})$ in the linear model (Equation 20), so the size of the true regression coefficients θ gets smaller with increasing sample size *n*. This is the case of practical interest, because for larger θ it would be trivial to differentiate between $H_0: \theta = 0$ and H_1^n , and for smaller θ it would be too difficult (Johnson 2005, p. 691). Under such a sequence of alternatives, the coefficient of determination R^2 and the *F*-statistic *f* tend to zero as the sample size goes to infinity. In contrast, the deviance (or likelihood ratio test) statistic

$$z = 2 \log \left[\frac{\max_{\alpha, \theta} f(\mathbf{y} \mid \alpha, \theta, H_1)}{\max_{\alpha} f(\mathbf{y} \mid \alpha, H_0)} \right]$$

has a limiting distribution in this setting (Johnson 2008), so it is of order O(1). For fixed deviance z and fixed g > 0, we then obtain

$$\lim_{n \to \infty} \operatorname{BF}(f) = \operatorname{BF}(z),$$
28.

where

BF(z) =
$$(g+1)^{d/2} \exp\left(-\frac{g}{g+1}\frac{z}{2}\right)$$
 29.

is a test-based Bayes factor based on the deviance z; see Section A.2.2 for the proof of this convergence result.

4.2. Generalized Linear Models

As mentioned in Section 2.4, test-based Bayes factors based on the deviance can be applied in a wider context, including GLMs. To keep notation simple, we consider a GLM with linear




Figure 5

Minimum Bayes factors based on the deviance for different dimensions $d = \dim(\theta)$ under (*a*) simple and (*b*) local alternatives as a function of *p*-values. Under local alternatives based on the *g*-prior, the $-e p \log p$ calibration (Equation 15) (*blue line*) is obtained for dimension d = 2, and the Edwards minimum Bayes factor (Equation 12) (*purple line*) is obtained for $d \to \infty$.

predictor vector $\eta = \alpha \mathbf{1} + \mathbf{X}\theta$ and test H_0 : $\theta = \mathbf{0}$ against the alternative H_1 : $\theta \neq \mathbf{0}$. However, the approach can easily be generalized to null hypotheses where only subvectors of θ are fixed (Hu & Johnson 2009).

Under regularity conditions, we have the well-known result that under H_0 the deviance z has an asymptotic chi-squared distribution $\chi^2(d)$ with d degrees of freedom, where $d = \dim(\theta)$ is the dimension of the parameter of interest. The deviance z = z(p) is then a one-to-one function of the corresponding p-value $p = \Pr(\chi^2(d) \ge z)$.

To obtain the limiting distribution under the alternative H_1 , we again consider alternatives of the form $H_1^n: \theta = O(n^{-1/2})$. Under such a sequence of alternatives and some regularity conditions, the distribution of the deviance converges to a noncentral chi-squared distribution with *d* degrees of freedom and noncentrality parameter $\lambda = O(1)$ (Davidson & Lever 1970, Held et al. 2015).

4.2.1. Simple alternatives. The test-based Bayes factor $BF(z) = f(z | H_0)/f(z | H_1)$ compares the likelihood of *z* under the asymptotic central and noncentral chi-squared distribution. The corresponding minimum Bayes factor can be obtained numerically by maximizing the noncentral chi-squared density of *z* under the alternative H_1 with respect to λ .

The minimum Bayes factors are very similar for different dimensions d; see **Figure 5**a. For larger p-values, we see the expected ordering of the minimum Bayes factors with larger values for smaller d. For p < 0.1, the minimum Bayes factors are all below the $-e p \log p$ calibration, but only slightly larger than the Edwards bound.

4.2.2. Local alternatives. Expression 29 can also be derived directly as a test-based Bayes factor based on the deviance statistic *z*, as proposed by Johnson (2008). Assume the generalized *g*-prior $\theta \mid H_1 \sim N(\mathbf{0}, g\mathbf{I}_{\theta,\theta}^{-1})$, where g > 0 and $\mathbf{I}_{\theta,\theta}$ denotes the expected Fisher information matrix for θ . This prior is only used implicitly in the derivation and corresponds to a gamma prior with mean $d \cdot g$ and scale parameter 2g on the noncentrality parameter $\lambda = \theta^{\top} \mathbf{I}_{\theta,\theta} \theta$ of the asymptotic

noncentral chi-squared distribution for the deviance z under the sequence of alternatives H_1^n . The implied approximate marginal distribution of $z | H_1$ is then gamma with mean d(g + 1) and scale parameter 2(g + 1) (Johnson 2008, theorem 2), which serves as marginal likelihood $f(z | H_1)$ under the alternative. The marginal likelihood $f(z | H_0)$ under the null hypothesis can be obtained with g = 0. With these prerequisites, we can derive the test-based Bayes factor BF(z) given by Equation 29 of H_0 versus H_1 for fixed g. For example, for d = 1 and large sample size n, Equation 29 is equivalent to equation (7) proposed by Wakefield (2009) in the context of genome-wide association studies (because the deviance and the squared Wald statistic are asymptotically equivalent).

To determine the minimum Bayes factor, we maximize the marginal likelihood $f(z|H_1)$ with respect to g and obtain the estimate

$$\hat{g}_{\text{ML}} = \max\{z/d - 1, 0\}.$$
 30.

Inserting Equation 30 into Equation 29 then gives (Johnson 2008, Held et al. 2015)¹

$$\min BF(z) = \begin{cases} \left(\frac{z}{d}\right)^{d/2} \exp\left(-\frac{z-d}{2}\right) & \text{for } z > d\\ 1 & \text{otherwise.} \end{cases}$$
31.

For any fixed *p*-value $p = \Pr(\chi^2(d) \ge z)$, this minimum Bayes factor (Equation 31) decreases monotonically as *d* increases (see **Figure 5***b*). In some special cases, the minimum Bayes factor given by Equation 31 corresponds to minimum Bayes factors from the literature introduced in Section 2, all shown in **Figure 5***b*: For d = 1, minBF(*z*) is equivalent to the local normal alternatives bound (Equation 14), and Held et al. (2015) show that for d = 2, where $z = -2 \log(p)$, minBF(*z*) reduces to the $-e p \log p$ calibration (Equation 15). Furthermore, as the dimension *d* tends to infinity, minBF(*z*) tends to the Edwards minimum Bayes factor minBF(*t*) (Equation 12) with onesided *t*-value; see Section A.3.1 for the proof. The same dependence of the minimum Bayes factor on the dimension *d* was reported by Sellke et al. (2001, table 4) for a slightly different class of local priors.

We now return to the example mentioned in Section 1.3.2. We consider a publicly available subgroup of the GUSTO-I (Global Utilisation of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries I) trial with n = 2,188 patients (Steyerberg 2009). In order to develop a prediction model for the binary endpoint 30-day survival after acute myocardial infarction, we focus on the assessment of the effects of 17 covariates listed in Held et al. (2015, table 1) using a logistic regression analysis. Note that two potential predictors are categorical variables with three and four levels, respectively. Application of Bayes factors based on the deviance to a logistic regression results in **Table 4**, where we list for each covariate the corresponding deviance *z*, the dimension *d* of the parameter of interest, the *p*-value *p*, and the minimum Bayes factor (Equation 31). Note that the deviance is always calculated based on a comparison of the full model with the model where the covariate of interest has been removed. Note also that d = 3 for the factor variable "Killip class" with four levels, d = 2 for the factor variable "smoking" with three levels (never/ex/current) and d = 1 for the remaining variables.

There are six variables with no evidence and another five variables with only weak evidence for an association with the outcome. Three covariates show overwhelming evidence for an association (minBF < 1/1000), and the remaining three covariates show moderate to substantial evidence with minimum Bayes factors between 1/4.9 and 1/19.

¹This is a correction of the formula given by Held et al. (2015) in the case $z \le d$.

	Deviance z	Dimension d	<i>p</i> -Value	Minimum Bayes factor
Gender	2.75	1	0.097	1/1.4
Age	75.72	1	< 0.0001	<1/1000
Killip class	38.68	3	< 0.0001	<1/1000
Diabetes	0.19	1	0.67	1
Hypotension	19.33	1	< 0.0001	<1/1000
Tachycardia	9.12	1	0.003	1/19
Anterior infarct location	1.93	1	0.16	1/1.1
Previous myocardial infarction	5.97	1	0.015	1/4.9
Height	0.63	1	0.43	1
Weight	2.28	1	0.13	1/1.3
Hypertension history	1.93	1	0.16	1/1.1
Smoking history	0.66	2	0.72	1
Hypercholesterolemia	0.51	1	0.48	1
Previous angina pectoris	0.68	1	0.41	1
Family history	0.45	1	0.50	1
ST elevation on ECG	8.72	1	0.003	1/16
Persistent chest pain	1.72	1	0.19	1/1.1

Table 4Output from a logistic regression model to identify important predictors of 30-daysurvival in the GUSTO-I study

For each parameter of interest, the table shows the deviance *z* with dimension *d*, the *p*-value, and the associated minimum Bayes factor (Equation 31) for local alternatives based on the *g*-prior. Abbreviation: GUSTO-I, Global Utilisation of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries I.

4.3. Combining Evidence

Suppose now that several two-sided *p*-values p_1, \ldots, p_n are available from *n* independent studies, for example, from different clinical trials to investigate the efficacy of the same treatment. How can we combine the statistical evidence available from those studies into one minimum Bayes factor? Deviance-based Bayes factors provide a convenient tool for doing so. One option would be to compute the test-based minimum Bayes factor (Equation 31) based on the deviance $z_i = z(p_i)$ for each *p*-value p_i with associated dimension d_i , and then compute the overall minimum Bayes factor as the product

$$\prod_{i=1}^{n} \min BF(z_i).$$
 32.

To see why we are taking the product of the minimum Bayes factors, note that the Bayes factor for the combined evidence equals the product of the Bayes factors $BF(z_i)$, i = 1, ..., n, for the single studies by sequential updating of Bayes factors (see Goodman 2016 for a practical example). We are interested in the minimum of this product Bayes factor, which has the product of the single minimum Bayes factors minBF(z_i) as a lower bound.

A sharper bound can be obtained by an application of Fisher's method to combine *p*-values from independent studies (Fisher 1958). He suggested computing $z_+ = \sum_{i=1}^{n} z_i$, where $z_i = -2 \log(p_i)$ is in fact the deviance test statistic with d = 2. Fisher argued that, under H_0 , each z_i follows a chi-squared distribution with two degrees of freedom, so z_+ is chi-squared with $d_+ = 2n$ degrees

of freedom, which can be used to calculate a combined *p*-value $p_+ = \Pr(\chi^2(2n) \ge z_+)$. To calculate the associated minimum Bayes factor, we can therefore use Equation 31 (with d = 2n) based on z_+ . This approach gives a sharper (i.e., larger) bound than the product minBF with equality if all *p*-values are identical. The approach can in fact be applied for any dimensions d_i , i = 1, ..., n. Then $d_+ = \sum_{i=1}^n d_i$ and the same inequality between the product minBF and the combined minBF still holds; see Section A.3.2 for the proof.

For illustration, consider the original example from Fisher (1958, section 22.1), where three tests of significance yield the *p*-values $p_1 = 0.145$, $p_2 = 0.263$, and $p_3 = 0.087$, and Fisher's method gives the combined *p*-value $p_+ = 0.076$. The product minimum Bayes factor (Equation 32) (with d = 2) is then 1/2.4 (0.42) whereas the minimum Bayes factor based on the combined *p*-value (with d = 6) is 1/2.2 (0.46), which is slightly larger in accordance with the proof in Section A.3.2. If instead the *p*-values are based on dimension d = 1, then the combined *p*-value is $p_+ = 0.098$ and the product minimum Bayes factor (Equation 32) is 1/1.9 (0.53), whereas the minimum Bayes factor based on the combined *p*-value (now with d = 3) is 1/1.7 (0.58).

5. DISCUSSION AND OUTLOOK

The main findings of this review are summarized as summary points below. We close now with two extensions of the methodology described.

5.1. Sample-Size Adjusted Bayes Factors in Generalized Linear Models

For GLMs, marginal likelihoods under local priors on the vector of regression coefficients θ , such as generalized *g*-priors, are typically not available in closed form, so they need to be computed by numerical techniques (numerical integration or Monte Carlo methods). Bayes factors based on the deviance statistic are therefore especially appealing for GLMs as they significantly simplify computations. However, these Bayes factors are not adjusted for sample size.

An alternative approach, which allows for sample size adjustments and is also computationally efficient, is to derive approximate data-based Bayes factors in closed form by applying analytical approximations—so-called integrated Laplace approximations (Wang & George 2007, Li & Clyde 2016). For example, by applying the Li & Clyde (2016) methodology, an approximate, sample-size adjusted minimum Bayes factor for 2×2 contingency tables can be obtained in closed form (Ott & Held 2017). By studying the relationship between this minimum Bayes factor and two-sided *p*-values from Fisher's exact test, Ott & Held (2017) conclude that the maximal evidence of these *p*-values is inversely related to sample size. This is the same qualitative relationship as in the linear model; see Section 3.2 and **Figure 4**.

5.2. Interval Null Hypotheses

One criticism of point null significance testing is that exact point null hypotheses rarely arise in practice. Instead, researchers often aim to test if a parameter is close to the null value θ_0 , which corresponds to an interval null hypothesis of the form $H_0: \theta \in (\theta_0 - b, \theta_0 + b)$ for some small b. However, Berger & Sellke (1987, p. 114) argue that "for a large number of problems testing a point null hypothesis is a good approximation to the actual problem." They state that if b is small, the minimum Bayes factor for the interval null hypothesis $H_0: \theta \in (\theta_0 - b, \theta_0 + b)$ is essentially equivalent to the minimum Bayes factor for the corresponding point null hypothesis $H_0: \theta = \theta_0$ if the same class of alternatives is considered. A similar argument is provided by Johnson (2016).

A. APPENDIX: SOME MATHEMATICAL RESULTS

A.1. The Folded Normal Distribution

A folded normal random variable $X \sim FN(\mu, \sigma^2)$ has density function

$$f(x) = \begin{cases} \frac{1}{\sigma} \left[\varphi\left(\frac{x-\mu}{\sigma}\right) + \varphi\left(\frac{x+\mu}{\sigma}\right) \right] & \text{if } x \ge 0\\ 0 & \text{else.} \end{cases}$$

If X is normal, i.e., $X \sim N(\mu, \sigma^2)$, then $|X| \sim FN(\mu, \sigma^2)$.

A.2. Results for Sample-Size Adjusted Bayes Factors

In this section, we establish two convergence results in the linear model: one for the minimum Bayes factor based on the F-statistic and the other for the Bayes factor.

A.2.1. Convergence of the minimum Bayes factor based on the *F*-statistic to the $-e q \log q$ calibration. Here we derive the minimum Bayes factor given by Equation 25 and show convergence to the $-e q \log q$ calibration (Equation 16) for $d \rightarrow \infty$.

Proof. Let n = d + 3, so $f \sim F(d, 2)$ under H_0 . In this case Equation 24 simplifies (for f > 1) to

minBF(f) =
$$\left(\frac{1+2/d}{f+2/d}\right)^{(d+2)/2} f^{d/2}$$
, 33.

and there is a closed-form expression for the *F*-statistic as a function of the *p*-value:

$$f = \frac{2}{d} \left[(1-p)^{-2/d} - 1 \right]^{-1}.$$
 34.

Hence, f > 1 is equivalent to $p < 1 - (1 + 2/d)^{-d/2}$ and that threshold converges from below to 1 - 1/e as $d \to \infty$. By plugging Equation 34 into Equation 33 and simplifying the expression, we find

minBF(f) =
$$\underbrace{(d+2) \frac{1-(1-p)^{2/d}}{2}}_{\to -\log(1-p) \text{ for } d\to \infty} \underbrace{\left(\frac{d+2}{d}\right)^{d/2}}_{\to e \text{ for } d\to \infty} (1-p),$$

so we obtain

$$\lim_{d\to\infty} \min \mathrm{BF}(f) = -e \ (1-p) \ \log(1-p),$$

which is what we wanted to show.

A.2.2. Convergence of the Bayes factor based on the *F*-statistic to the Bayes factor based on the deviance. Here we show the convergence (Equation 28) of the Bayes factor based on the *F*-statistic (Equation 23) to the Bayes factor based on the deviance (Equation 29) for $n \to \infty$.

Proof. By assumption, the deviance z and g > 0 are fixed. First, we express the testbased Bayes factor BF(f) (Equation 23) as a function of the deviance z instead of the F-statistic f by using Equation 21 and the identity $R^2 = 1 - \exp(-z/n)$. This yields

BF(f) =
$$(g + 1)^{-(n-d-1)/2} \left[g \exp\left(-\frac{z}{n}\right) + 1 \right]^{(n-1)/2}$$

414 Held • Ott

Rearranging the above formula gives

$$\lim_{n \to \infty} \operatorname{BF}(f) = (g+1)^{d/2} \lim_{n \to \infty} \left[\frac{g \exp\left(-\frac{z}{n}\right) + 1}{g+1} \right]^{(n-1)/2}$$

By using the series expansion of the exponential $\exp(-z/n)$ and the result $\lim_{n\to\infty} (1+x/n)^{n-1} = \exp(x)$ for $x \in \mathbb{R}$, we obtain the limit

$$\lim_{n \to \infty} \left[\frac{g \exp\left(-\frac{z}{n}\right) + 1}{g + 1} \right]^{(n-1)/2} = \exp\left(-\frac{g}{g + 1} \frac{z}{2}\right),$$

which completes the proof.

A.3. Results for Large-Sample Bayes Factors

In this section, two results related to the large-sample minimum Bayes factor based on the deviance (Equation 31) are proven: first, a convergence result as the degrees of freedom of the deviance tend to infinity, and then, the fact that the product minimum Bayes factor does not exceed the combined minimum Bayes factor.

A.3.1. Convergence of the minimum Bayes factor based on the deviance. Here we show convergence of the minimum Bayes factor given by Equation 31 to the Edwards bound (Equation 12) for $d \rightarrow \infty$, adapting the proof from Held et al. (2015, appendix B).

Proof. The Edwards bound given by Equation 12 is minBF(t) = exp($-t^2/2$) with $t = t(p) = \Phi^{-1}(1-p)$ for any p < 0.5. For large d, it is then sufficient to consider the case z > d, where the minimum Bayes factor (Equation 31) is

minBF(z) =
$$\left(\frac{z}{d}\right)^{d/2} \exp\left(-\frac{z-d}{2}\right);$$

here, z is the (1 - p)-quantile of the chi-squared distribution with d degrees of freedom. We will show that for $d \to \infty$ and fixed p-value p < 0.5, the ratio minBF(z)/ exp $(-t^2/2)$ is 1.

First, note that with $d \to \infty$, the standardized chi-squared distribution converges to a standard normal, so $(z - d)/\sqrt{2d} \stackrel{a}{\sim} N(0, 1)$ and hence $z \approx d + \sqrt{2d} t$. Plugging this into Equation 31, we obtain

$$\frac{\min BF(z)}{\exp(-t^2/2)} \approx \left(\frac{d+\sqrt{2dt}}{d}\right)^{d/2} \exp\left(-\sqrt{\frac{d}{2}t} + t^2/2\right)$$
$$= \exp\left[-at + a^2\log(1+t/a) + t^2/2\right]$$

with $a = \sqrt{d/2}$. Now for large d, the term t/a is small, and hence we can apply a second-order Taylor expansion of $\log(1 + x) \approx x - x^2/2$ around x = 0. This yields

$$\frac{\min \text{BF}(z)}{\exp(-t^2/2)} \approx \exp\left[-at + a^2\left(\frac{t}{a} - \frac{t^2}{2a^2}\right) + \frac{t^2}{2}\right] = \exp(0) = 1,$$

which proves the statement.

A.3.2. Combining minimum Bayes factors. Here we prove the claim made in Section 4.3 that the product minimum Bayes factor is smaller than or equal to the combined minimum Bayes factor based on $z_{+} = \sum_{i=1}^{n} z_{i}$ and establish when equality holds.

Proof. Note that the minimum Bayes factor given by Equation 31 is obtained by minimizing the Bayes factor given by Equation 29 with respect to g. We thus start by considering the product and the combined Bayes factor based on Equation 29. This product Bayes factor is

$$\prod_{i=1}^{n} BF(z_i) = \prod_{i=1}^{n} \left[(g_i + 1)^{d_i/2} \exp\left(-\frac{g_i}{g_i + 1} \frac{z_i}{2}\right) \right]$$
$$= \prod_{i=1}^{n} (g_i + 1)^{d_i/2} \exp\left(-\sum_{i=1}^{n} \frac{g_i}{g_i + 1} \frac{z_i}{2}\right)$$
35.

and the combined Bayes factor based on z_+ with $d_+ = \sum_{i=1}^n d_i$ is

BF(z_+) =
$$(g+1)^{d_+/2} \exp\left(-\frac{g}{g+1}\frac{z_+}{2}\right)$$
. 36.

For $g_i = g$ for all i = 1, ..., n, the product Bayes factor (Equation 35) is equal to the combined Bayes factor (Equation 36). To obtain the product minimum Bayes factor, each g_i in Equation 35 is optimized separately to minimize the corresponding term for i = 1, ..., n. This leads to a minimum Bayes factor that does not exceed the combined minimum Bayes factor obtained by choosing g to minimize Equation 35 under the restriction $g_i = g$ for all i = 1, ..., n. It follows that the product minimum Bayes factor cannot be larger than the combined minimum Bayes factor.

To see when equality holds, note that the estimates of g_i for the product minimum Bayes factor are $\hat{g}_i = \max\{z_i/d_i - 1, 0\}$ and the estimate of g for the combined minimum Bayes factor is $\hat{g} = \max\{z_+/d_+ - 1, 0\}$. So equality holds if all z_i (or equivalently all p_i) and all d_i are equal or if $z_i < d_i$ for all i = 1, ..., n.

SUMMARY POINTS

- 1. *p*-Values are indirect measures of the evidence against a point null hypothesis H_0 . Bayes factors provide a quantitative summary of the direct evidence against H_0 .
- p-Values can be transformed to minimum Bayes factors. A minimum Bayes factor quantifies the maximal evidence of a p-value against a point null hypothesis within a certain class of alternative hypotheses.
- 3. The maximal evidence of a *p*-value depends on how the *p*-value has been calculated. It generally decreases with increasing sample size but increases with increasing dimension of the parameter of interest. These features should be taken into account when *p*-values are transformed to minimum Bayes factors in routine applications.
- 4. The maximal evidence of a *p*-value also depends on the underlying study design: It matters whether the *p*-value comes from a confirmatory study with a well-defined simple alternative or from an exploratory analysis used to generate hypotheses, where local alternatives are more appropriate.

5. The commonly used $-e p \log p$ calibration represents a lower bound on the Bayes factor for local alternatives on scalar parameters (d = 1) in large samples, but not necessarily for small samples or for larger dimensions of the parameter of interest.

DISCLOSURE STATEMENT

The authors are not aware of any affiliations, memberships, funding, or financial holdings that might be perceived as affecting the objectivity of this review.

ACKNOWLEDGMENTS

This work was supported by the Swiss National Science Foundation (project #159715).

LITERATURE CITED

Bayarri MJ, Benjamin DJ, Berger JO, Sellke TM. 2016. Rejection odds and rejection ratios: a proposal for
statistical practice in testing hypotheses. J. Math. Psychol. 72:90-103
Bayarri MJ, Berger JO, Forte A, García-Donato G. 2012. Criteria for Bayesian model choice with application
to variable selection. Ann. Stat. 40:1550-77
Benjamin DJ, Berger JO, Johannesson M, Nosek BA, Wagenmakers E-J, et al. 2017. Redefine statistical
significance. Nat. Hum. Behav. http://dx.doi.org/10.1038/s41562-017-0189-z
Berger J. 2006. The case for objective Bayesian analysis. Bayesian Anal. 1:385-402
Berger JO, Sellke T. 1987. Testing a point null hypothesis: the irreconcilability of P values and Der
evidence (with discussion). J. Am. Stat. Assoc. 82:112-39 Baye
Bernardo JM, Smith AFM. 2000. Bayesian Theory. Chichester, UK: Wiley diffe
Berry DA. 2016. p-Values are not what they're cracked up to be. Am. Stat. 70. http://www.tandfonline.
com/doi/full/10.1080/00031305.2016.1154108 alter
Bland M. 2015. An Introduction to Medical Statistics. Oxford, UK: Oxford Univ. Press. 4th ed.
Casella G, Berger RL. 1987. Reconciling Bayesian and frequentist evidence in the one-sided testing problem.
J. Am. Stat. Assoc. 82:106–11
Cox DR. 2006. Principles of Statistical Inference. Cambridge, UK: Cambridge Univ. Press
Cox DR, Donnelly CA. 2011. Principles of Applied Statistics. Cambridge, UK: Cambridge Univ. Press
Davidson RR, Lever WE. 1970. The limiting distribution of the likelihood ratio statistic under a class of local A ce
alternatives. Sankbya Ser. A 32:209–24 intro
Donahue RMJ. 1999. A note on information seldom reported via the P value. Am. Stat. 53:303–6 Baye
Edwards W, Lindman H, Savage LJ. 1963. Bayesian statistical inference for psychological research. inclu
Psychol. Rev. 70:193–242 sect
Fisher RA. 1958. Statistical Methods for Research Workers. Edinburgh: Oliver & Boyd. 13th ed. Baye
Good IJ. 1950. Probability and the Weighing of Evidence. London: Griffin
Goodman SN. 1999a. Toward evidence-based medical statistics. 1: The <i>p</i> value fallacy. Ann. Intern.
Med. 130:995–1004 min
Goodman SN. 1999b. Toward evidence-based medical statistics. 2: The Bayes factor. Ann. Intern. as an
Med. 130:1005–13 p-va
Goodman SN. 2005. P value. In Encyclopedia of Biostatistics, ed. P Armitage, T Colton, pp. 3921–25. Chichester, rese
UK: Wiley. 2nd ed.
Goodman SN. 2008. A dirty dozen: twelve p-value misconceptions. Semin. Hematol. 45:135-40
Goodman SN. 2016. Aligning statistical and scientific reasoning. Science 352:1180-81
Greenland S, Poole C. 2013. Living with <i>p</i> values: resurrecting a Bayesian perspective on frequentist statistics.
Epidemiology 24:62–68

Derivation of minimum Bayes factors for different classes of alternatives, including symmetric and local alternatives.

A celebrated introduction to the Bayesian paradigm; ncludes a pioneering section on minimum Bayes factors.

Two papers advocating minimum Bayes factors as an alternative to *p*-values in medical research.

	Greenland S, Senn SJ, Rothman KJ, Carlin JB, Poole C, et al. 2016. Statistical tests, <i>p</i> values, confidence intervals, and power: a guide to misinterpretations. <i>Eur. J. Epidemiol.</i> 31:337–50
	Held L. 2010. A nomogram for p values. BMC Med. Res. Methodol. 10:21Held L, Gravestock I, Sabanés Bové D. 2016. Objective Bayesian model selection for Cox regression. Stat.
	Med. 35:5376–90
A sample-size adjusted	Held L, Ott M. 2016. How the maximal evidence of <i>p</i> -values against point null hypotheses depends
calibration of <i>p</i> -values is	on sample size. Am. Stat. 70:335-41
proposed.	Held L, Sabanés Bové D, Gravestock I. 2015. Approximate Bayesian model selection with the deviance statistic. <i>Stat. Sci.</i> 30:242–57
	 Hu J, Johnson VE. 2009. Bayesian model selection using test statistics. <i>J. R. Stat. Soc. B</i> 71:143–58 Hung HMJ, O'Neill RT, Bauer P, Kohne K. 1997. The behavior of the <i>p</i>-value when the alternative hypothesis is true. <i>Biometrics</i> 53:11–22
Bayes factors based on	Jeffreys H. 1961. <i>Theory of Probability</i> . Oxford, UK: Oxford Univ. Press. 3rd ed. Johnson VE. 2005. Bayes factors based on test statistics. <i>J. R. Stat. Soc. B</i> 67:689–701
test statistics are	Johnson VE. 2008. Properties of Bayes factors based on test statistics. <i>J. N. Stat.</i> 30: B 07:009–701 Johnson VE. 2008. Properties of Bayes factors based on test statistics. <i>Scand. 7. Stat.</i> 35:354–68
introduced.	Johnson VE. 2006. Properties of Bayes factors based on test statistics. <i>Statut. 5: 554–66</i> Johnson VE. 2016. Comments on the "ASA Statement on Statistical Significance and <i>P</i> -values"
	and marginally significant <i>p</i> -values. <i>Am. Stat.</i> 70. http://www.tandfonline.com/doi/full/10.1080/ 00031305.2016.1154108
	Johnson VE, Rossell D. 2010. On the use of non-local prior densities in Bayesian hypothesis tests. J. R. Stat. Soc. B 72:143–70
	Kass RE, Raftery AE. 1995. Bayes factors. J. Am. Stat. Assoc. 90:773-95
	Lee PM. 2004. Bayesian Statistics: An Introduction. London: Wiley. 3rd ed.
	Li Y, Clyde MA. 2016. Mixtures of g-priors in generalized linear models. arXiv:1503.06913v2 [stat.ME]
	Liang F, Paulo R, Molina G, Clyde MA, Berger JO. 2008. Mixtures of g priors for Bayesian variable selection. <i>J. Am. Stat. Assoc.</i> 103:410–23
	Lindley DV. 1957. A statistical paradox. Biometrika 44:187-92
	Marsman M, Wagenmakers E-J. 2017. Three insights from a Bayesian interpretation of the one-sided <i>p</i> value. <i>Educ. Psychol. Meas.</i> 77:529–39
	Matthews JNS. 2006. Introduction to Randomized Controlled Clinical Trials. Boca Raton, FL: Chapman & Hall/CRC. 2nd ed.
	Matthews R, Wasserstein R, Spiegelhalter D. 2017. The ASA's <i>p</i> -value statement, one year on. <i>Significance</i> 14:38–41
	Ott M, Held L. 2017. Bayesian calibration of p-values from Fisher's exact test. Tech. Rep., Univ. Zurich
	Ramsey F, Schafer D. 2002. <i>The Statistical Sleuth: A Course in Methods of Data Analysis</i> . Belmont, CA: Duxbury. 2nd ed.
A comprehensive paper on the $-e p \log p$	 Royall RM. 1986. The effect of sample size on the meaning of significance tests. <i>Am. Stat.</i> 40:313–15 Sellke T, Bayarri MJ, Berger JO. 2001. Calibration of <i>p</i> values for testing precise null hypotheses. <i>Am. Stat.</i> 55:62–71
calibration gives different derivations.	Spiegelhalter DJ, Abrams KR, Myles JP. 2004. <i>Bayesian Approaches to Clinical Trials and Health-Care Evaluation</i> . New York: Wiley
	Stephens M, Balding DJ. 2009. Bayesian statistical methods for genetic association studies. <i>Nat. Rev. Genet.</i> 10:681–90
	Steyerberg EW. 2009. Clinical Prediction Models. New York: Springer
	Tukey JW. 1980. We need both exploratory and confirmatory. Am. Stat. 34:23–25
	Vovk VG. 1993. A logic of probability, with application to the foundations of statistics (with discussion and a reply by the author). J. R. Stat. Soc. B 55:317–51
	Wagenmakers E-J. 2007. A practical solution to the pervasive problems of <i>p</i> values. <i>Psychon. Bull. Rev.</i> 14:779–804
	Wakefield J. 2009. Bayes factors for genome-wide association studies: comparison with <i>p</i> -values. <i>Genet. Epi-</i> <i>demiol.</i> 33:79–86
	Wang X, George EI. 2007. Adaptive Bayesian criteria in variable selection for generalized linear models. <i>Stat.</i> <i>Sin.</i> 17:667–90

418 Held • Ott

- Wasserstein RL, Lazar NA. 2016. The ASA's statement on *p*-values: context, process, and purpose. *Am. Stat.* 70:129–33
- Yuan Y, Johnson VE. 2008. Bayesian hypothesis tests using nonparametric statistics. Stat. Sin. 18:1185–200
- Zellner A. 1986. On assessing prior distributions and Bayesian regression analysis with g-prior distributions. In Bayesian Inference and Decision Techniques: Essays in Honor of Bruno de Finetti, ed. PK Goel, A Zellner, pp. 233–43. Amsterdam: North-Holland